NFKB1 and Alzheimer disease: The O-GlcNAc modification of NF‐κB p65 has been identified in astrocytes in vitro and in vivo, and increasing O-GlcNAcylation with GlcNAc inhibits inflammation and activation of astrocytes in AD mice by repressing the NF-κB signalling pathway [16].